Related Experiment Video
Updated: Oct 3, 2025
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Melatonin suppresses the metastatic potential of osteoblastic prostate cancers by inhibiting integrin α2 β1
Huai-Ching Tai1,2, Shih-Wei Wang3,4,5, Sanskruti Swain6
1School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
Abstract:
Advanced prostate cancer often develops into bone metastasis, which is characterized by aberrant bone formation with chronic pain and lower chances of survival. No treatment exists as yet for osteoblastic bone metastasis in prostate cancer. The indolamine melatonin (N-acetyl-5-methoxytryptamine) is a major regulator of the circadian rhythm. Melatonin has shown antiproliferative and antimetastatic activities but has not yet been shown to be active in osteoblastic bone lesions of prostate cancer. Our study investigations reveal that melatonin concentration-dependently decreases the migratory and invasive abilities of two osteoblastic prostate cancer cell lines by inhibiting FAK, c-Src, and NF-κB transcriptional activity via the melatonin MT1 receptor, which effectively inhibits integrin α2 β1 expression. Melatonin therapy appears to offer therapeutic possibilities for reducing osteoblastic bone lesions in prostate cancer.
Insights
Melatonin (N-acetyl-5-methoxytryptamine) may treat advanced prostate cancer bone metastasis. This study shows melatonin inhibits cancer cell migration and invasion, offering new therapeutic options for osteoblastic bone lesions.
Area of Science:
- Oncology
- Endocrinology
- Cell Biology
Background:
- Advanced prostate cancer frequently metastasizes to bone, causing osteoblastic lesions, pain, and reduced survival.
- Current treatments for prostate cancer osteoblastic bone metastasis are lacking.
- Melatonin, a circadian rhythm regulator, exhibits antiproliferative and antimetastatic properties.
Purpose of the Study:
- To investigate the efficacy of melatonin in treating osteoblastic bone metastasis in prostate cancer.
- To elucidate the molecular mechanisms by which melatonin affects prostate cancer cell behavior in bone microenvironments.
Main Methods:
- Utilized two osteoblastic prostate cancer cell lines.
- Assessed the effect of melatonin on cell migration and invasion.
- Investigated the inhibition of focal adhesion kinase (FAK), c-Src, and nuclear factor-kappa B (NF-κB) transcriptional activity.
- Examined the role of the melatonin MT1 receptor and integrin α2 β1 expression.
Main Results:
- Melatonin significantly decreased the migratory and invasive capabilities of prostate cancer cells in a concentration-dependent manner.
- Melatonin inhibited FAK, c-Src, and NF-κB transcriptional activity.
- The observed effects were mediated through the melatonin MT1 receptor, leading to the inhibition of integrin α2 β1 expression.
Conclusions:
- Melatonin demonstrates therapeutic potential for reducing osteoblastic bone lesions in advanced prostate cancer.
- Melatonin's mechanism involves inhibiting key signaling pathways and cell adhesion molecules crucial for metastasis.
